Ana Isabel Padrao
Overview
Explore the profile of Ana Isabel Padrao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reis-Mendes A, Ferreira M, Padrao A, Duarte J, Duarte-Araujo M, Remiao F, et al.
Inflammation
. 2023 Oct;
47(1):264-284.
PMID: 37833616
Doxorubicin (DOX) is a topoisomerase II inhibitor used in cancer therapy. Despite its efficacy, DOX causes serious adverse effects, such as short- and long-term cardiotoxicity. This work aimed to assess...
2.
Louis J, Bennett S, Owens D, Tiollier E, Brocherie F, A S Carneiro M, et al.
J Appl Physiol (1985)
. 2022 Dec;
133(6):1433-1440.
PMID: 36509417
No abstract available.
3.
Reis-Mendes A, Padrao A, Duarte J, Goncalves-Monteiro S, Duarte-Araujo M, Remiao F, et al.
Biomolecules
. 2021 Nov;
11(11).
PMID: 34827723
Doxorubicin (DOX) is a topoisomerase II inhibitor commonly used in the treatment of several types of cancer. Despite its efficacy, DOX can potentially cause fatal adverse effects, like cardiotoxicity. This...
4.
Reis-Mendes A, Dores-Sousa J, Padrao A, Duarte-Araujo M, Duarte J, Seabra V, et al.
Pharmaceuticals (Basel)
. 2021 Jun;
14(6).
PMID: 34073506
Mitoxantrone (MTX) is a pharmaceutical drug used in the treatment of several cancers and refractory multiple sclerosis (MS). Despite its therapeutic value, adverse effects may be severe, namely the frequently...
5.
Nogueira-Ferreira R, Ferreira R, Padrao A, Oliveira P, Santos M, Kavazis A, et al.
J Physiol Biochem
. 2019 Oct;
75(4):561-572.
PMID: 31620967
Aerobic exercise training induces a unique cardioprotective phenotype, but it is becoming clear that it does not promote the same structural, functional, and molecular adaptations in both ventricles. In the...
6.
Montero-Bullon J, Melo T, Ferreira R, Padrao A, Oliveira P, Domingues M, et al.
Sci Rep
. 2019 Sep;
9(1):13423.
PMID: 31530825
Cancer associated body wasting is the cause of physical disability, reduced tolerance to anticancer therapy and reduced survival of cancer patients and, similarly to cancer, its incidence is increasing. There...
7.
Padrao A, Nogueira-Ferreira R, Vitorino R, Carvalho D, Correia C, Neuparth M, et al.
Arch Biochem Biophys
. 2018 Mar;
645:12-18.
PMID: 29548774
Limiting cancer-induced cardiac damage has become an increasingly important issue to improve survival rates and quality of life. Exercise training has been shown to reduce cardiovascular complications in several diseases;...
8.
Padrao A, Ferreira R, Amado F, Vitorino R, Duarte J
Proteomics
. 2015 Dec;
16(5):816-30.
PMID: 26632760
Exercise training has been recommended as a nonpharmacological strategy for the prevention and attenuation of skeletal muscle atrophy in distinct pathophysiological conditions. Despite the well-established phenotypic alterations, the molecular mechanisms...
9.
Moreira-Goncalves D, Ferreira R, Fonseca H, Padrao A, Moreno N, Silva A, et al.
Basic Res Cardiol
. 2015 Oct;
110(6):57.
PMID: 26463598
Clinical studies suggest that aerobic exercise can exert beneficial effects in pulmonary arterial hypertension (PAH), but the underlying mechanisms are largely unknown. We compared the impact of early or late...
10.
Moreira-Goncalves D, Padrao A, Ferreira R, Justino J, Nogueira-Ferreira R, Neuparth M, et al.
Biochim Biophys Acta
. 2015 Oct;
1852(12):2722-31.
PMID: 26456917
No abstract available.